Patients with renal cell carcinoma (RCC) are more likely to experience long-term response to axitinib (Inlyta, Pfizer) if they have early and significant tumor shrinkage and continue the treatment for an extended period, a new study suggests (Target Oncol 2017 Mar 30. [Epub ahead of print], PMID: 28361451).
Investigators in the United States, Germany and Japan analyzed data from two clinical trials in which 402 treatment-naive patients with advanced RCC were treated with axitinib. They compared